A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Persistence of the Effect of Oral Monthly Ibandronate on Bone Reception in Postmenopausal Women in Osteoporosis
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 203
- 主要终点
- Change in serum levels of CTX-I (log-transformed fraction) from Week 9 to Week 12
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of an investigational drug in postmenopausal women with osteoporosis. The primary hypothesis of this study is that in postmenopausal women with osteoporosis, oral monthly ibandronate, at doses of 100 mg and 150 mg, does not achieve persistence in reduction of bone resorption throughout the monthly dosing interval, as demonstrated by a larger change in the serum carboxyterminal crosslinked telopeptide of Type I collagen (CTX-I) log-transformed fraction from baseline four weeks post dose compared to one week post dose, during the third month of treatment, in the participants taking ibandronate than in the participants taking placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •postmenopausal for at least 3 years, with osteoporosis at any of the following sites: [BMD > 2.0 standard deviations below young normal mean bone mass for the hip trochanter, PA lumbar spine (L1 to L4), total hip, or femoral neck based on the normative database provided by each individual manufacturer].
- •willing to take study-supplied calcium and vitamin D supplement (or equivalent) and to discontinue any non-study calcium supplements for run-in period and the duration of the study.
排除标准
- •pregnant or lactating, or of childbearing potential.
- •participated in another therapeutic trial with an investigational compound within 30 days of randomization.
- •history of hypersensitivity to any component of ibandronate tablets or has hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
- •an abnormality of the esophagus which delays esophageal emptying such as stricture or achalasia.
- •unable to stand or sit upright for at least 60 minutes once a month.
- •current use of illicit drugs, or history of drug or alcohol abuse within the past five years.
- •has any of the following: hypocalcemia; any severe malabsorption syndrome; moderate or severe hypertension which is uncontrolled; new onset angina or myocardial infarction within six months of entry into the study; evidence for impaired renal function; organ transplantation; or other significant end organ diseases (genitourinary, cardiovascular, endocrine, hepatic, psychiatric, renal, hematologic, or pulmonary).
- •history of or evidence of metabolic bone disease (other than postmenopausal bone loss).
- •clinical fracture in the past year.
- •is receiving or has received treatment prior to randomization which might influence bone turnover.
- •is receiving or expected to receive during the course of the study any medication (other than study medication) which might alter bone or calcium metabolism, including Vitamin A in excess of 10,000 IU per day or Vitamin D in excess of 5000 IU per day, calcitonin, phenytoin, heparin, or lithium.
研究组 & 干预措施
Placebo
Participants will receive 3 placebo tablets once a month, for 3 months, on the first day of each treatment cycle.
干预措施: Placebo (Drug)
ibandronate 100 mg
Participants will receive 2 ibandronate 50 mg tablets and 1 placebo tablet once a month, for 3 months, on the first day of each treatment cycle.
干预措施: ibandronate (Drug)
ibandronate 150 mg
Participants will receive 3 ibandronate 50 mg tablets once a month, for 3 months, on the first day of each treatment cycle.
干预措施: ibandronate (Drug)
结局指标
主要结局
Change in serum levels of CTX-I (log-transformed fraction) from Week 9 to Week 12
时间窗: Baseline, Week 9, Week 12
次要结局
未报告次要终点